The broad societal value of pembrolizumab for women’s cancer in Canada
Broadening the perspective to include additional value elements considerably increased the overall value of treatment of women's cancer compared with the TPP, indicating that the perspective used by health technology bodies may not fully capture the societal value of therapeutics.
Authors
- Matthew Madin-Warburton
- Kathryn Mishkin (ORCID: https://orcid.org/0000-0003-0050-8106)
- Kate Young (ORCID: https://orcid.org/0000-0001-5637-9871)
- K. Patterson (ORCID: https://orcid.org/0009-0009-4423-0098)
- Annabelle Davies
- Marie-Claude Meilleur
- Elizabeth Brook
- Nishini Wijenayake
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- MSD (UK) Limited (United Kingdom) (GB)
- Merck Canada Inc. (Canada) (CA)
- Instituto Nacional de Medicina Tropical (AR)
Publication Details
- Journal
- Future Oncology
- Published
- 2026-03-13
- DOI
- https://doi.org/10.1080/14796694.2026.2639738
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00